Using Test of SCM for Detection Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00407706|
Recruitment Status : Unknown
Verified December 2006 by Ziv Hospital.
Recruitment status was: Recruiting
First Posted : December 5, 2006
Last Update Posted : December 5, 2006
In our previous research, we have shown that women that have breast cancer have a population of lymphocytes that recognizes specific antigen and there cytoplasmic matrix goes through physical change a short time after exposure in vitro to the same antigen. This change can be measured by polarization changes of fluorescent light emitted by FDA (fluorescein diacetate) labeled cells. Further test that we performed showed that those differences are also shown in a benign situation that known as indicator for a high risk for developing breast cancer within 10-15 years. The incidence of the expression of these lymphocytes correlates with the histopathological picture as it is related in high risk for the developing the disease.
In this work we will expand the scope of the procedure to early detection of the cancerous process in breast lesions by Fitzgibbon's risk categories for the development invasive carcinoma of the breast. In the proposed work we intend to use specific antigen MUC1 for breast cancer. This study is a continuation of our published work in the "The Breast "
|Condition or disease||Intervention/treatment|
|Malignant Breast Cancer, Benign Breast Lesions||Procedure: blood test|
|Study Type :||Observational|
|Estimated Enrollment :||180 participants|
|Observational Model:||Defined Population|
|Official Title:||Breast Cancer- Early Detection of Cancer Disease and Pre-Cancer Disease, and in Women That Are at High Risk for Developing Breast Cancer by Identifying Lymphocytes Previously Exposed to Specific Cancer Antigen.|
|Study Start Date :||December 2006|
|Estimated Study Completion Date :||December 2010|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00407706
|Contact: Amram Hadari, MD||+ 972 6828923|
|Contact: Tali Keren, MA||+972 4 email@example.com|
|Safed, Israel, 13110|
|Contact: Amram Hadari, MD + 972 4 6828923|
|Contact: Tali Keren, MA + 972 4 682 8828|
|Principal Investigator: Amram Hadari, MD|
|Sub-Investigator: Tali Keren, MA|
|Principal Investigator:||Amram Hadari, MD||Surgery Department|